Use of powerful anticoagulants to prevent pulmonary embolism may actually lead to more deaths
They argue for a revision of the American College of Chest Physicians' guidelines, in light of their review showing that the use of powerful anticoagulants to prevent pulmonary embolism may actually lead to more deaths among patients who take these drugs.
New anticoagulant dabigatran has a significantly higher rate of complications than warfarin when used in a real-world setting, a new analysis concludes.